Liver steatosis and nonalcoholic steatohepatitis: from pathogenesis to therapy.
Non-alcoholic fatty liver disease refers to a disease spectrum that ranges from steatosis to non-alcoholic steatohepatitis, which leads to fibrosis, cirrhosis and hepatocellular carcinoma. Given the increasing prevalence of obesity worldwide, the incidence of non-alcoholic fatty liver disease has become a world health problem. Non-alcoholic fatty liver disease is considered to be the hepatic manifestation of metabolic syndrome associated with insulin resistance, central obesity, and type 2 diabetes mellitus. Allegedly, insulin resistance plays a pivotal role in its pathogenesis. Here we highlight non-alcoholic fatty liver disease epidemiology and pathophysiology, its progression towards steatohepatitis with particular emphasis in liver fibrosis and participation of advanced glycation end products. The different treatments reported are described here as well. We conducted a search in PubMed with the terms steatohepatitis, steatosis advanced glycation end products, liver fibrosis and adipocytokines. Articles were selected according to their relevance.
Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México, México; Secretaria de Salud del Distrito Federal, Servicios de Salud Pública del Distrito Federal, Ciudad de México, México. Address: Avenida San Rafael Atlixco 186, Colonia Vicentina, Ciudad de México, México. Email: sila@xanum.uam.mx.
Elizabeth
E
Hernández-Pérez
Secretaria de Salud del Distrito Federal, Servicios de Salud Pública del Distrito Federal, Ciudad de México, México.
Plácido Enrique
PE
León García
Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México, México.
Norma Edith
NE
López-Díazguerrero
Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México, México.
Fernando
F
Rivera-Cabrera
Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Ciudad de México, México.
Elizabeth
E
Del Ángel Benítez
 adipocytokines;  advanced glycation end products;  liver fibrosis;  liver steatosis; non-alcoholic fatty liver disease